PMID- 34621178 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211009 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 12 DP - 2021 TI - Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study. PG - 753653 LID - 10.3389/fphar.2021.753653 [doi] LID - 753653 AB - Purpose: This real-world study evaluated the effectiveness of different inhalation therapies in patients with symptomatic chronic obstructive pulmonary disease (COPD) in China and also explored the relevant factors that influence the effectiveness of inhalation therapy. Patients and Methods: We conducted a multicenter prospective longitudinal study that was carried out in 12 hospitals in China from December 2016 to June 2021. A face-to-face interview was conducted to collect data. Baseline data were collected at the first visit. Minimum clinically important difference (MCID) was defined as attaining a COPD assessment test (CAT) decrease >/=2. We mainly assessed the MCID and the incidence of exacerbations at the 6 months follow-up. Results: In 695 patients, the mean age was 62.5 +/- 8.2 years, with a mean CAT score of 15.1 +/- 6.0. Overall, 341 (49.1%) patients attained the MCID of CAT and the incidence of exacerbation during follow-up was 22.3%. Females were significantly more likely to attain MCID than male in COPD patients (adjusted odd ratio (aOR) = 1.93, adjusted 95% confidence interval (a95%CI) = 1.09-3.42, p = 0.024). Patients treated with LABA/LAMA or ICS/LABA/LAMA (ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist) were more likely to attain MCID than patients treated with LAMA (aOR = 3.97, a95%CI = 2.48-6.35, p < 0.001; aOR = 3.17, a95%CI = 2.09-4.80, p < 0.001, respectively). Patients treated with LABA/LAMA had a higher incidence of severe exacerbation than patients treated with ICS/LABA/LAMA (aOR = 1.95, a95%CI = 1.04-3.66, p = 0.038). Conclusion: The incidence of MCID in symptomatic COPD patients treated with inhalation therapy was nearly 50%. Patients treated with LABA/LAMA or ICS/LABA/LAMA were more likely to attain MCID than patients treated with LAMA. Patients treated with LABA/LAMA had a higher incidence of severe exacerbations than with ICS/LABA/LAMA. CI - Copyright (c) 2021 Cheng, Duan, Zhou, Zhao, Yi, Liu, Deng, Li, Zeng, Peng, Song, Lin, Yang and Chen. FAU - Cheng, Wei AU - Cheng W AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Duan, Jiaxi AU - Duan J AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zhou, Aiyuan AU - Zhou A AD - Department of Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, China. FAU - Zhao, Yiyang AU - Zhao Y AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Yi, Rong AU - Yi R AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, China. FAU - Liu, Yi AU - Liu Y AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, China. FAU - Deng, Dingding AU - Deng D AD - Department of Respiratory Medicine, The First Affiliated People's Hospital, Shaoyang College, Shaoyang, China. FAU - Li, Xin AU - Li X AD - Division 4 of Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha, China. FAU - Zeng, Yuqin AU - Zeng Y AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Peng, Yating AU - Peng Y AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Song, Qing AU - Song Q AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Lin, Ling AU - Lin L AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Yang, Min AU - Yang M AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Chen, Ping AU - Chen P AD - Department of Pulmonary and Critical Care Medicine, Research Unit of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Disease, The Second Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article DEP - 20210921 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC8490668 OTO - NOTNLM OT - COPD assessment test (CAT) OT - COPD-chronic obstructive pulmonary disease OT - MCID (minimal clinically important differences) OT - exacerbation OT - inhalation therapy OT - real-world OT - symptomatic COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/09 06:00 MHDA- 2021/10/09 06:01 PMCR- 2021/09/21 CRDT- 2021/10/08 07:06 PHST- 2021/08/05 00:00 [received] PHST- 2021/09/09 00:00 [accepted] PHST- 2021/10/08 07:06 [entrez] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/10/09 06:01 [medline] PHST- 2021/09/21 00:00 [pmc-release] AID - 753653 [pii] AID - 10.3389/fphar.2021.753653 [doi] PST - epublish SO - Front Pharmacol. 2021 Sep 21;12:753653. doi: 10.3389/fphar.2021.753653. eCollection 2021.